Skip to Content

Vonvendi Approval History

FDA Approved: Yes (First approved December 8, 2015)
Brand name: Vonvendi
Generic name: von willebrand factor (recombinant)
Dosage form: for Injection
Company: Baxalta Incorporated
Treatment for: von Willebrand's Disease

Vonvendi [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (VWF) indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease.

Development History and FDA Approval Process for Vonvendi

DateArticle
Apr 17, 2018Approval FDA Approves Vonvendi [von Willebrand factor (recombinant)] for Perioperative Management of Bleeding in Adult Patients with von Willebrand Disease
Dec  8, 2015Approval FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide